Furthest along
29 approved
18 in Phase 3
Drugs
77
in active trials · 432 in all
Trials
191 active
1296 since 2021
Drugs77
| Drug | How it works | Partner | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Calcitonin gene-related peptide receptor antagonist |
Approved | 29 Nov 2026soonPhase 3 trial completes | |||
| Next date | 29 Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Acute Treatment of Migraine, Migraine and 3 more | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | 2 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 2 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Alopecia Areata, Severe Alopecia Areata and 5 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in China | 11 Dec 2026soonPhase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | 11 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Urothelial Carcinoma, Breast Neoplasms and 14 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 30 Dec 2026Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Locally Advanced or Metastatic ER+ HER2- Breast Cancer and 3 more | ||||
| Open drug page | |||||
— |
Rigel Pharmaceuticals · Arvinas |
Approved | 30 Dec 2026Phase 3 trial completes | ||
| Next date | 30 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Breast Cancer, Locally Advanced or Metastatic ER+ HER2- Breast Cancer and 3 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 31 Dec 2026Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Advanced Malignancies, NSCLC and 16 more | ||||
| Open drug page | |||||
ALK/ROS1 inhibitor |
Approved | 31 Dec 2026Phase 3 trial completes | |||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NSCLC, Carcinoma, Non-Small-Cell Lung and 6 more | ||||
| Open drug page | |||||
PARP inhibitor |
Approved | 31 Dec 2026Phase 3 trial completes | |||
| How it works | Blocks PARP | ||||
| Next date | 31 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | mCRPC, Prostate Cancer and 5 more | ||||
| Open drug page | |||||
— |
Approved | 18 Jan 2027Phase 3 trial completes | |||
| Next date | 18 Jan 2027 · Phase 3 trial completes | ||||
| Also tested for | Respiratory Syncytial Virus (RSV), Lower Respiratory Tract Illness and 2 more | ||||
| Open drug page | |||||
Anti-epileptic agent |
Viatris |
Approved | 31 Jan 2027Phase 4 trial completes | ||
| Next date | 31 Jan 2027 · Phase 4 trial completes | ||||
| Open drug page | |||||
Androgen receptor inhibitor |
Astellas |
Approved | 28 Feb 2027Phase 3 trial completes | ||
| How it works | Blocks the male hormone testosterone from acting on cells | ||||
| Next date | 28 Feb 2027 · Phase 3 trial completes | ||||
| Also tested for | Prostate Cancer, Hormone Sensitive Prostate Cancer and 14 more | ||||
| Open drug page | |||||
— |
Approved | 4 Mar 2027Phase 2 trial completes | |||
| Next date | 4 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Pneumococcal Disease | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | 17 Mar 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 17 Mar 2027 · Phase 3 trial completes | ||||
| Also tested for | Ulcerative Colitis | ||||
| Open drug page | |||||
Aztreonam-Avibactamnot checked |
— |
Approved in the EU | 31 Mar 2027Phase 2 trial completes | ||
| Next date | 31 Mar 2027 · Phase 2 trial completes | ||||
| Also tested for | Gram-negative Bacterial Infections, Gram-negative Bacterial Infection | ||||
| Open drug page | |||||
Janus kinase inhibitor |
Approved | 2 May 2027Phase 3 trial completes | |||
| How it works | Blocks JAK enzymes that pass on immune signals | ||||
| Next date | 2 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Atopic Dermatitis, Eczema | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 4 Aug 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 4 Aug 2027 · Phase 3 trial completes | ||||
| Also tested for | Multiple Myeloma, Relapsed/Refractory Multiple Myeloma | ||||
| Open drug page | |||||
Calcitonin gene-related peptide receptor antagonist |
Approved | 12 Aug 2027Phase 1 trial completes | |||
| Next date | 12 Aug 2027 · Phase 1 trial completes | ||||
| Also tested for | Acute Treatment of Migraine | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 31 Dec 2027Phase 3 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 31 Dec 2027 · Phase 3 trial completes | ||||
| Also tested for | HER2-positive Breast Cancer, Biliary Tract Neoplasms and 30 more | ||||
| Open drug page | |||||
Kinase inhibitor |
Approved | 21 Mar 2028Phase 4 trial completes | |||
| How it works | Blocks a kinase | ||||
| Next date | 21 Mar 2028 · Phase 4 trial completes | ||||
| Also tested for | Carcinoma, Non-Small-Cell Lung, NSCLC and 2 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 10 Sep 2028Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 10 Sep 2028 · Phase 3 trial completes | ||||
| Also tested for | Hemophilia A, Hemophilia B and 2 more | ||||
| Open drug page | |||||
No drugs match “”.
SEC filings33
Since Jan 2024 · All on SEC.gov- 3 NovReported quarterly results · SEC 8-K
- 3 NovChanged a director or officer · SEC 8-K
- 4 AugReported quarterly results · SEC 8-K
- 18 JunChanged a director or officer · SEC 8-K
- 18 JunMade a public disclosure · SEC 8-K
- 5 MayReported quarterly results · SEC 8-K
- 27 AprFiled a report · SEC 8-K
- 3 FebReported quarterly results · SEC 8-K
- 16 Dec 2025Made a public disclosure · SEC 8-K
- 21 Nov 2025Reported other events · SEC 8-K
- 20 Nov 2025Offered new securities · 1 prospectus (424B5)
- 18 Nov 2025Offered new securities · 1 prospectus (424B3)
- 13 Nov 2025Reported other events · SEC 8-K
- 4 Nov 2025Reported quarterly results · SEC 8-K
- 5 Aug 2025Reported quarterly results · SEC 8-K
- 19 May 2025Reported other events · SEC 8-K
- 15 May 2025Offered new securities · 1 prospectus (424B5)
- 13 May 2025Offered new securities · 1 prospectus (424B3)
- 29 Apr 2025Reported quarterly results · SEC 8-K
- 28 Apr 2025Filed a report · SEC 8-K
- 4 Feb 2025Reported quarterly results · SEC 8-K
- 17 Dec 2024Made a public disclosure · SEC 8-K
- 29 Oct 2024Reported quarterly results · SEC 8-K
- 15 Oct 2024Changed a director or officer · SEC 8-K
- 30 Jul 2024Reported quarterly results · SEC 8-K
- 26 Jul 2024Changed a director or officer and reported other events · SEC 8-K
- 10 Jul 2024Changed a director or officer · SEC 8-K
- 1 Jul 2024Changed a director or officer · SEC 8-K
- 22 May 2024Filed a report · SEC 8-K
- 1 May 2024Reported quarterly results · SEC 8-K
- 29 Apr 2024Filed a report · SEC 8-K
- 30 Jan 2024Reported quarterly results · SEC 8-K
- 10 Jan 2024Reported other events · SEC 8-K
About
- No active trial
- 355 other drugs
- Registry names
- 7 names in ClinicalTrials.gov Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seagen, a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Seagen Inc.
Metsera, a wholly owned subsidiary of Pfizer
Array Biopharma, now a wholly owned subsidiary of Pfizer - Sources
- ClinicalTrials.gov updated 16 Nov 2026 · SEC filings Industry-sponsored drug trials since 2021 · Logos provided by Logo.dev